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Abstract
Association testing of multiple correlated phenotypes offers better power than univariate analysis of single traits. We
analyzed 6,600 individuals from two population-based cohorts with both genome-wide SNP data and serum metabolomic
profiles. From the observed correlation structure of 130 metabolites measured by nuclear magnetic resonance, we
identified 11 metabolic networks and performed a multivariate genome-wide association analysis. We identified 34 genomic
loci at genome-wide significance, of which 7 are novel. In comparison to univariate tests, multivariate association analysis
identified nearly twice as many significant associations in total. Multi-tissue gene expression studies identified variants in
our top loci, SERPINA1 and AQP9, as eQTLs and showed that SERPINA1 and AQP9 expression in human blood was associated
with metabolites from their corresponding metabolic networks. Finally, liver expression of AQP9 was associated with
atherosclerotic lesion area in mice, and in human arterial tissue both SERPINA1 and AQP9 were shown to be upregulated
(6.3-fold and 4.6-fold, respectively) in atherosclerotic plaques. Our study illustrates the power of multi-phenotype GWAS and
highlights candidate genes for atherosclerosis.
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Five years of genome-wide association studies (GWAS) have
successfully identified common variants at .1,000 genomic loci
robustly associated with a wide range of human conditions and
quantitative traits [1]. Despite this progress, one limitation is that
almost all GWAS performed to date have focused on single traits,
even in studies involving multiple related phenotypes. Growing
evidence for pleiotropy [2,3], where the same locus is associated
with multiple phenotypes, supports the idea that multivariate
analysis of multiple phenotypes can provide a substantial boost in
power for locus discovery, consistent with simulation studies [4–7].
A plethora of metabolites in blood have been described as risk
factors for metabolic syndrome, atherosclerosis and coronary
artery disease [8,9]. Using high-throughput nuclear magnetic
resonance assays, quantitative profiles of 130 metabolites in two
population-based cohorts from Finland, the Cardiovascular Risk
in Young Finns Study (YFS) [10] and the Northern Finland Birth
Cohort 1966 (NFBC66) [11] have been determined. These
metabolites included lipoprotein subclasses of VLDL, LDL, IDL
and HDL as well as lipids, amino acids and other small molecules
(Materials S1).
Figure 1 illustrates the general flow of our study. We first
applied an unsupervised algorithm to identify networks from the
observed correlation structure amongst the 130 metabolite
measures in 6,600 individuals. For each of these networks, we
performed a multivariate test of association for 2.5 million SNPs
[4]. Because we also tested all SNPs for association to each
metabolite separately, we can assess the relative gain in power of
the multivariate approach. To interpret the novel signals, we
tested whether the associated SNPs influenced cis-gene expression
levels in multiple tissues as well as whether the expression of
candidate genes was associated to specific metabolites that drive
the initial association. Finally, we analysed arterial tissue from
mouse and man to test for a relation between our top candidate
genes and atherosclerosis plaques.
Results
Genotype and phenotype data
We analysed genotype and phenotype data from the YFS
(N=1,905) [10,12] and the NFBC66 (N=4,703) [11,13]. For both
YFS and NFBC66, we imputed SNP genotypes using the MACH
algorithm [14] and the HapMap Phase 2 reference panel [15].
Serum collected from both cohorts underwent metabolomic
profiling on the same proton nuclear magnetic resonance
(NMR) platform [16]. The NMR metabolomics platform used
here provided absolute quantitative information on 130 distinct
metabolic measures [17]. Metabolite levels for both cohorts were
normalized and adjusted for age, gender, cohort, and population
structure (Materials and Methods).
Identification of metabolic networks
After correcting for cohort effects and pooling the metabolomic
data for YFS and NFBC66, we constructed a Pearson correlation
matrix that defined the pairwise relationships between all
metabolites and applied agglomerative hierarchical clustering in
order to identify networks of metabolites (Figure 2). Using a
dynamic, data-driven tree-cutting algorithm [18], we identified 11
metabolic networks that represent various metabolic pathways
(Materials and Methods and Figure S1). Additional information
for each metabolic network, including full descriptions, abbrevi-
ations, inter-metabolite correlations, and supporting association
analyses, is given in the Materials S1. Briefly, metabolic network 1
comprises multiple measures related mainly to cholesterol
metabolism in the apoB-containing lipoproteins. Metabolic
network 2 includes branched-chain and aromatic amino acids
together with the large TG-rich VLDL particles and serum
triglycerides. Metabolic networks 3 and 4 capture the larger and
smaller particles of HDL-metabolism, respectively. Metabolic
networks 5, 6, 7, and 8 are related to lipid poly-unsaturation,
ketone bodies, the glucose-alanine cycle, and renal function,
respectively. Metabolic networks 9, 10, and 11 each contain only 2
metabolites and represent measures of fatty acid chain length and
composition, mean diameter of LDL and double-bonding of fatty
acid chains, urea and acetate, respectively.
Genome-wide association analysis
For each of the 11 metabolic networks, we performed SNP
association testing using a multivariate test based on Canonical
Correlation Analysis and Wilks’ lambda [4]. Each association test
yielded an F statistic, corresponding P value, and a loading for
each metabolite in the network to indicate the relative contribution
of that metabolite to the overall association (Materials and
Methods). For univariate analysis, we used standard linear
regression where each of the 130 metabolites was regressed onto
each SNP.
The implementation of dimensionality reduction and multivar-
iate analysis allowed us to select essentially independent tests based
on the correlation structure of the phenotype data. Using
multivariate analysis, we tested each SNP only 11 times (one per
metabolic network). A Bonferroni correction for testing each SNP
to 130 metabolites is overly conservative, since the metabolites are
partially correlated, but still common practice [16,19,20].
Accordingly, we set genome-wide significance thresholds at
P,4.5610
29 and P,3.8610
210 for multivariate and univariate
analysis, respectively.
To maximize power, we performed a joint analysis of both
cohorts, correcting for population structure and cohort-specific
effects. We observed little evidence for test statistic inflation,
lambda range 1.01–1.06 (Materials and Methods and Table S1).
Across all 11 metabolic networks, the joint multivariate analysis
yielded 713 SNPs significantly associated with one or more
metabolic networks (P,4.5610
29). This corresponded to 34
distinct loci and 75 significant locus-network associations overall
(Table 1 and Materials and Methods). Loci were considered novel
Author Summary
In this study, we aim to identify novel genetic variants for
metabolism, characterize their effects on nearby genes,
and show that the nearby genes are associated with
metabolism and atherosclerosis. To discover new genetic
variants, we use an alternative approach to traditional
genome-wide association studies: we leverage the infor-
mation in phenotype covariance to increase our statistical
power. We identify variants at seven novel loci and then
show that our top signals drive expression of nearby genes
AQP9 and SERPINA1 in multiple tissues. We demonstrate
that AQP9 and SERPINA1 gene expression, in turn, is
associated with metabolite levels. Finally, we show that the
genes are associated with atherosclerosis using mouse
atherosclerotic lesion size (AQP9) as well as tissue from
healthy human arteries and atherosclerotic plaques (AQP9
and SERPINA1). This study illustrates that multivariate
analysis of correlated metabolites can boost power for
gene discovery substantially. Further functional work will
need to be performed to elucidate the biological role of
SERPINA1 and AQP9 in atherosclerosis.
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significance with a metabolite or other metabolic phenotype in
the NHGRI Catalogue of Published GWAS [1] and if they were
independent of other proximal signals (Materials and Methods and
Table S2). Of the 34 loci detected, 27 were previously identified to
be associated with fasting glucose levels [21,22], total measures of
LDL, HDL and triglycerides [23,24], bradykinin [25], glutamine
[16,25], alanine-valine ratio [16], phenylalanine [16], citrate [16],
and sphingolipids [26]. Overall, we found 7 novel loci associated
with 12 metabolic networks in total (Table 1).
In comparing multivariate and univariate P values for a given
SNP, we selected the lowest univariate P value for any single
metabolite in a given network. We found that multivariate tests
yielded more significant P values, reflecting increased power
compared to univariate tests (Figure S2). In terms of number of
significant associations, multivariate analysis outperformed uni-
variate in both cohorts. When their respective genome-wide
significance thresholds are applied, multivariate analysis uncov-
ered 75 locus-metabolic network associations, whereas univariate
analysis found only 40 (almost all of which were detected by
multivariate analysis), leading to the detection of 7 novel loci
instead of one (Figure 3). This demonstrates the relative gain of
multivariate testing compared to univariate testing. Notably,
multivariate analysis still uncovered more associations (69% more)
than univariate analysis even when applying the more stringent
genome-wide threshold for 130 independent metabolites. Multi-
variate also outperformed univariate when assessing only known
loci, i.e. those with prior genome-wide significant association to
metabolites in the NHGRI Catalogue of Published GWAS [1]
(Figure S3).
From the multivariate analysis, our strongest association signal
overall was due to a nonsynonymous SNP, rs1303 (Glu400Asp)
located in the last exon of SERPINA1. This variant was associated
with metabolic networks 1 and 2 (P=5.4 610
248 and P=7.4 610
222,
respectively; Figure S4). To explore the extent to which rs1303
perturbs protein structure, we utilized the PolyPhen2 algorithm [27].
PolyPhen2 predicted the Glu to Asp mutation to be benign (naı ¨ve
Bayes posterior probability=0.0 and 0.005 for the HumDiv and
HumVar training sets, respectively). The next strongest signal overall
was an intronic SNP (rs16939881) at the AQP9 locus, associated with
metabolic networks 1, 2, 3, and 4 (P=2.9 610
227, P=4.9 610
215,
P=2.3 610
218 and P=2.0 610
214, respectively; Figure S4). The
metabolic network associations at AQP9 remained highly significant
after conditioning on the previously identified LIPC locus, 250 Kb
downstream (Table S2). We focus on our two top signals for
subsequent in-depth analyses. Because our top signals are within the
SERPINA1 and AQP9 genes, we assume these to be the most likely
candidate genes.
Fine-mapping and conditional analysis of SERPINA1 and
AQP9
Using the 1000 Genomes Phase I integrated variant set and the
IMPUTE2 algorithm [28], we generated denser maps of genetic
variants for the SERPINA1 and AQP9 loci. We then performed a
multivariate test for each SNP with metabolic networks 1–4 as well
as a conditional analysis to ascertain any independent signals in
each region.
After 1000 Genomes imputation, rs1303 remained the top
signal at the SERPINA1 locus for metabolic networks 1 and 2.
Conditioning on rs1303 revealed an independent association
between another nsSNP, rs28929474, and metabolic networks 1
and 2 (P=1.7610
219 and P=3.7610
213 respectively) (Figure S5).
Rs28929474 (Glu366Lys) lies in the last exon of SERPINA1 and,
unlike rs1303, it was predicted by PolyPhen2 to be a probable
damaging mutation with a naı ¨ve Bayes posterior probability=1.0
for both HumDiv and HumVar.
Imputation of the AQP9 locus with the 1000 Genomes panel yielded
less confidently inferred genotypes than the HapMap2 panel at the top
SNP rs16939881 (posterior probability .0.90 for a genotype call).
Consequently we had less power at rs16939881, however it still
remained significantly associated with metabolic networks 1, 2, and 3.
Even with reduced power, conditional analysis showed that the signal
at AQP9 could be explained by rs16939881 alone (Figure S6).
Novel variants drive expression of SERPINA1 and AQP9 in
multiple tissues
We next investigated metabolic network associated variants for
eQTL effects on SERPINA1 and AQP9. We used three resources
(a) the DILGOM cohort, a Finnish population-based cohort
(N=518) with gene expression data (from whole blood) and serum
metabolomic data [29], (b) a subset of the EUFAM study (N=54)
Figure 1. Overview of the study design.
doi:10.1371/journal.pgen.1002907.g001
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neous adipose tissue gene expression data, and (c) the Human
Liver Cohort, a Caucasian cohort (HLC; N=178) with liver tissue
gene expression data [31–33]. These three resources also comprise
genome-wide SNP data. We summarize the eQTL analyses in
Table S3.
In the DILGOM study, the SNP explaining the most variance
in SERPINA1 expression (rs11628917; linear regression
P=6.0610
210; adjusted R
2=0.07) was also strongly associated
with metabolic networks 1 and 2 from the YFS and NFBC66 joint
analysis (P=9.6610
214 and P=1.9610
211) (Figure 4). In our
data, there was moderate linkage disequilibrium (LD; r
2=0.47;
D9=0.99) between the top SERPINA1 SNP (rs1303) and the blood
eQTL (rs11628917). Conditional analysis showed that the
association of rs11628917 with both metabolic networks could
be explained by rs1303, suggesting non-independence. Rs1303
itself was nominally associated with SERPINA1 expression
(P=0.01). The independent signal at rs28929474 showed no
evidence of influencing SERPINA1 expression (and was not in LD
with any eQTLs), suggesting that its primary effect may be protein
structure destabilization. No blood eQTLs were detected for
AQP9.
In the EUFAM study, the top and bottom 10
th percentiles of
HDL-C concentrations (Finnish population age and sex specific
Figure 2. Serum metabolic networks. A Pearson correlation matrix of serum metabolites across both YFS and NFBC66 cohorts was hierarchically
clustered and the resulting heatmap and dendrogram are presented here with red indicating high positive correlation, blue high negative correlation,
and white no correlation. Clusters of tightly correlated metabolites, metabolic networks, are labeled 1–11.
doi:10.1371/journal.pgen.1002907.g002
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(N=19 and N=35, respectively). First, we tested for differences in
AQP9 and SERPINA1 between high and low HDL-C groups. Both
AQP9 and SERPINA1 expression were upregulated in adipose
tissue of individuals with low HDL-C (fold changes 3.47 and 2.29,
P=9.0610
24 and P=0.03, respectively). Analysis of genetic
variants did not yield any eQTLs at the AQP9 the locus. Given
the independent but proximal signals at AQP9 and LIPC, we did
detect an eQTL 210 Kb downstream within the LIPC locus that
influenced the adipose expression of AQP9 (rs1825955; P=4.8 610
23)
but not LIPC. There was low LD between rs1825955 and the top
multivariate AQP9 SNP rs16939881 (r
2=0.17; D9=0.94). SERPINA1
also did not harbour adipose eQTLs (including rs11628917, P.0.05),
indicating either potentially tissue-specific function of the SNP or lack
of statistical power.
The HLC allowed for the analysis of gene expression in the
human liver. In the HLC, we detected eQTLs for both SERPINA1
and AQP9(Figure 4). An eQTLinthepromoter region of SERPINA1
explained 3.9% of the liver expression of the gene (rs1884549;
P=4.3 610
23). Rs1884549 was also associated with metabolic
network 1 (P=9.6 610
222) and in moderate LD (r
2=0.38;
D9=0.99) with rs1303. A variant within AQP9 was associated with
its expression in the liver (rs16953360; P=4.6 610
23;a d j u s t e d
R
2=0.04) as well as metabolic networks 1–4 (P=1.0 610
225;
Table 1. Loci detected using joint multivariate association analysis.
Locus Top SNP Chr MAF
Top multivariate
Pvalue** Metabolic network Top metabolite* Novel
PCSK9, USP24 rs1998013 1p32.3 0.02 4.77E-13 1 IDL-FC# N
ANGPTL3, DOCK7 rs10889332 1p31.3 0.29 8.40E-15 1,2,3,4 MobCH# N
GALNT2 rs10127775 1q42.13 0.44 1.49E-09 1,3 L-HDL-PL N
APOB rs673548 2p24.1 0.27 9.64E-14 1,2,4 S-VLDL-TG# N
GCKR rs1260326 2p23.3 0.36 1.31E-12 2,3,4,7 S-HDL-P N
SLC1A4 rs10211524 2p14 0.39 3.13E-10 2 Val N
G6PC2 rs560887 2q24.3 0.31 3.57E-15 8 Glc# N
ADAMTS3 rs12507628 4q13.3 0.18 2.84E-09 4 S-HDL-L N
PPM1K, HERC6 rs1440581 4q22.1 0.47 1.05E-10 2 Val# N
CYP4V2, KLKB1 rs1912826 4q35.2 0.43 3.72E-12 2,4 Phe N
PFN3, F12, GRK6 rs2731672 5q35.3 0.27 3.15E-14 2 Phe N
ELOVL2 rs3798722 6p24.2 0.12 3.65E-09 5 DHA N
PPP1R3B, TNKS rs4841132 8p23.1 0.15 2.35E-09 4 M-HDL-FC N
LPL rs12678919 8p21.3 0.09 9.22E-13 1,2,3 M-VLDL-PL# N
ABCA1 rs4149310 9q31.1 0.1 2.31E-10 1,3 XL-HDL-P N
FADS1/2/3 rs102275 11q12 0.43 3.88E-264 1,2,3,4,5,9,10 LA# N
APOA1/C3/A4/A5 rs964184 11q23 0.14 8.44E-20 1,2,3,4 S-VLDL-P# N
SPRYD4, GLS2 rs2657880 12q13.2 0.14 7.08E-30 8 Gln# N
LIPC rs1532085 15q22.1 0.44 8.69E-104 1,2,3,4,10 XL-HDL-TG# N
CETP rs173539 16q13 0.28 2.78E-70 1,2,3,4,10 XS-VLDL-L# N
TAT rs4788815 16q22.3 0.35 4.02E-13 2 Tyr# N
HP, HPR, DHX38 rs217181 16q22.3 0.18 1.47E-36 2,6 Gp# N
GLTPD2, TM4SF5, VM01 rs12051548 17p13.2 0.06 1.08E-11 1 SM N
LDLR rs6511720 19p13.2 0.1 3.87E-09 4 Tot-CH N
APOE/C1/C2 rs445925 19q13.32 0.06 5.71E-42 1,3,4 L-LDL-FC# N
PLTP rs4810479 20q13.12 0.27 2.15E-42 1,2,3,4 XL-HDL-TG# N
GSC2, SLC25A1, CLTCL1 rs712964 22q11.21 0.41 2.94E-11 6 Cit# N
GC rs1851024 4q13.3 0.05 1.07E-14 1,4 Alb Y
CXCL5, PF4, PPBP rs16850360 4q13.3 0.03 3.40E-10 4 Alb Y
EREG rs2168889 4q13.3 0.05 5.76E-14 4 Alb Y
SERPINA1 rs1303 14q32.13 0.24 5.42E-48 1,2 IDL-C Y
AQP9 rs16939881 15q22.1 0.05 2.92E-27 1,2,3,4 XL-HDL-TG# Y
MYO1E, CCNB2, RNF111 rs2306786 15q22.2 0.17 9.55E-11 2 Tot-TG Y
ZFHX3 rs10500569 16q22.3 0.23 7.00E-12 2 Tyr Y
*Complete metabolic network loadings, indicating the relative contributions of single metabolites to the overall association, are given in Figure S4.
**Multiple test corrected significance threshold for a metabolic network association was P,4.5610
29.
#Indicates that the top metabolite was also detected by univariate test.
doi:10.1371/journal.pgen.1002907.t001
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214; P=8.1 610
218; P=7.1 610
214 respectively). SNPs
rs16953360 and rs16939881 are in very strong LD (r
2=0.97;
D9=0.98).
SERPINA1 and AQP9 expression is associated with
metabolites
We next investigated whether there was a relationship between
SERPINA1 and AQP9 and metabolites levels in the DILGOM
cohort. To do this, we considered those metabolic networks
associated with SERPINA1 and AQP9 SNPs then regressed
individual metabolite levels on gene expression (Table S4). Genetic
variation in AQP9 was associated with metabolic networks 1–4 and
here we observed significant association between expression of
AQP9 and two metabolites from network 1 (XL-HDL-TG:
P=8.5610
29; MobCH3: P=7.2610
25). SERPINA1 harboured
genetic variants associated with metabolic networks 1 and 2, and
expression of SERPINA1 was associated with eight metabolites,
four from metabolic network 1 and four from metabolic network 2
(Table S4).
SERPINA1 and AQP9 expression is associated with
atherosclerosis
Since genetic variation and gene expression of SERPINA1 and
AQP9 were associated with lipoprotein levels, lipid transporters
central to atherosclerosis, we investigated the relationship between
these genes and atherosclerosis.
We first investigated a mouse model (BxH-ApoE, N=298) on
a hyperlipidemic apolipoprotein-E (ApoE) null background with
liver gene expression profiles and quantified aortic lesions [34–
36]. BxH-ApoE consisted of an F2 population derived from a
backcross of mice highly susceptible to atherosclerosis (C57BL/6J
ApoE
2/2) and highly resistant (C3H/HeJ ApoE
2/2). The F2
population was then fed on a high-fat, western diet for 16 weeks
then euthanized at 24 weeks. Using linear regression, we tested
for association between liver expression of Serpina1a (the mouse
ortholog of SERPINA1) and AQP9 and the area of atherosclerotic
lesion in the aorta. Expression of AQP9 showed significant
association with atherosclerotic plaque area (P=5.0 610
23;
Figure 4), with samples in the top decile of AQP9 expression
having on average 29% larger lesion area than those in the
bottom decile. The association remained significant after
correction for gender, total cholesterol, triglycerides and HDL.
On this background, Serpina1a expression did not show associa-
tion with lesion area (P=0.58).
Finally, we utilized the Tampere Vascular Study (TVS) a
collection of atherosclerotic plaque samples from patients
undergoing peripheral vascular surgery (carotid and femoral
endarterectomy and aortic bypass procedures due to atheroscle-
rosis) and control samples from individuals undergoing coronary
artery by-pass surgery (Materials and Methods). In TVS, both
SERPINA1 and AQP9 showed strong association with lesion
status (Figure 4). AQP9 was expressed at a 4.67 fold higher
level in lesions compared to controls (Mann Whitney P=
4.64610
212), and similarly SERPINA1 exhibited 6.33 fold higher
expression (Mann Whitney P=2.49 610
213). The TVS results
suggest that both AQP9 and SERPINA1 are candidate genes for
atherosclerosis.
Discussion
We have empirically demonstrated the power of multivariate
association testing of metabolite networks. We detected 7 novel
loci and investigated the gene expression of our top loci,
SERPINA1 and AQP9, in multiple human tissues as well as their
potential role in atherosclerosis.
SERPINA1 was associated with metabolic networks 1 and 2 (top
metabolites: total cholesterol in IDL and mean diameter of VLDL,
respectively), which are mainly related to cholesterol and
triglyceride pathways of apoB-containing lipoproteins as well as
diabetes associated amino acids [37]. SERPINA1 encodes alpha 1-
antitrypsin (A1AT), a protease inhibitor that protects surrounding
tissues at sites of inflammation, and various studies have suggested
A1AT’s role in atherosclerosis. A1AT has been detected within
HDL particles but not LDL [38], although complexes of A1AT
and LDL have been found in the intimal arterial wall and in
human atherosclerotic lesions in the coronary artery [39].
Proteolytic degradation of LDL by murine peritoneal macrophag-
es has been shown to be enhanced by A1AT binding, and
immunostaining and in situ hybridization have also suggested that
A1AT is produced by macrophages in the arterial wall [39].
AQP9 encodes aquaporin 9, a liver glycerol channel [40], and
contains variants which showed association with metabolic
networks 1 and 2 (top metabolites: triglycerides in very large
HDL and mean diameter of VLDL) as well as networks 3 and 4
(top metabolites: mean diameter of HDL and phosphatidylcho-
line). The proximity of AQP9 to the well-known LIPC gene 250 Kb
downstream raises the question of whether the AQP9 and LIPC loci
harbour independent effects. Our conditional analyses of meta-
bolic network associated SNPs indicate that these are indeed
independent genetic signals. In addition, LIPC expression in whole
blood from DILGOM was not associated with metabolites from
the relevant networks 1, 2, 3, or 4, and LIPC liver expression in
mouse only slightly attenuated the association of AQP9 with
atherosclerotic lesion area in a linear model (P=0.059). In human
aorta, LIPC was nominally differentially expressed between
healthy and plaque samples (P=0.01) and did not affect the
substantially larger aortic differential expression of AQP9. Previous
experiments have shown AQP9’s involvement in gluconeogenesis.
AQP9 mRNA and protein have been shown to be greater in
Figure 3. Associations detected between genomic loci and
metabolic networks. A Venn diagram showing the number of
associations between all genomic loci and metabolic networks stratified
by joint multivariate and univariate analysis (for univariate, at least one
metabolite from a network need be associated).
doi:10.1371/journal.pgen.1002907.g003
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adipose tissue [41]. The opposite is true in liver, suggesting that
reduction in glycerol influx in hepatocytes via AQP9 could prevent
excessive lipid accumulation and may reduce hyperglycaemia in
obesity [41]. Further, AQP9
2/2 mice have previously been shown
to have elevated levels of plasma glycerol and triglycerides, and
inhibition of AQP9 by a small molecule inhibitor showed that it is
required for glycerol-dependent glucose production in murine
hepatocytes [42,43].
Our findings for SERPINA1 and AQP9 are consistent with the
above studies suggesting associations with cardiometabolic risk
factors and show that (a) common variants in both are associated
with metabolic networks, (b) these variants modulate gene
expression and suggest that there may be potential heterogeneous
genetic control in different tissues, (c) expression of both genes was
associated with metabolites from the relevant networks, and finally
(d) gene expression was positively associated with atherosclerotic
lesion area in mice (AQP9) and upregulated in atherosclerotic
Figure 4. Connecting genetic variation, gene expression, metabolites, and atherosclerosis for SERPINA1 and AQP9. (a) Boxplots show
SNPs associated with metabolic networks are also cis eQTLs for SERPINA1 (human blood and liver) and AQP9 (human liver). Boxplots consist of median
log2-normalised expression for each genotype with first and third quartiles designated by box edges. Whiskers extend to +/21.5 times interquartile
range. (b) Human blood expression of SERPINA1 and AQP9 was associated with metabolites derived from the same metabolic networks as their
corresponding genetic variants. Edge widths are proportional to the strength of association (P value). (c) Liver expression of AQP9 (but not SERPINA1)
in mice on a hyperlipidemic APOE
2/2 background showed significant positive association with aortic lesion area. (d) Boxplots for log2-normalised
expression of SERPINA1 and AQP9 in healthy human arterial tissue versus that for atherosclerotic plaques.
doi:10.1371/journal.pgen.1002907.g004
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the roles of SERPINA1 and AQP9 in atherosclerosis are tissue-
specific where AQP9 displays an effect in both liver and arterial
tissue and SERPINA1 only in the latter.
Of the five other novel loci, there were variants proximal to
ZFHX3 on Chr 16, MYO1E on Chr 15, as well as three
independent signals at 4q13. ZFHX3 encodes ATBF1, a
transcription factor involved in neuronal differentiation and
survival [44,45] that has also been previously implicated in
Kawasaki disease, atrial fibrillation and ischemic stroke [46,47].
Variants at the ZFHX3 locus were associated with metabolic
network 2 where the metabolite with the greatest loading was
tyrosine. Little is known about the role of the tyrosine in
circulation, however a recent study [37] investigating the
predictive ability of five amino acids for type 2 diabetes onset
suggested that amino acid metabolism, including tyrosine, plays a
role in the pathophysiology of metabolic syndrome, where it is
known that individuals with either metabolic syndrome and/or
diabetes are at increased risk for stroke. At 4q13, a band that
contains the ALB albumin gene, metabolic networks 1 and 4 were
associated with variants 30 Kb upstream of group-specific
component, a vitamin D binding protein (top metabolites:
triglycerides in IDL and albumin, respectively). Metabolic network
4, with albumin as the top metabolite, was also associated with
variants 10 Kb upstream of EREG and independent variants 8 Kb
upstream of CXCL5. EREG encodes epiregulin, part of a family of
epidermal growth factors for which there is evidence that osmotic
pressure has a role in signal transduction [48], and CXCL5 encodes
a cytokine that has previously been linked with obesity and insulin
resistance [49]. Finally, 15q22 harboured intronic variants within
the MYO1E gene, a non-muscle class I myosin protein, associated
with metabolic network 2 (top metabolite: total triglycerides).
Myosin 1E has previously been shown to bind phospholipids [50],
regulate podocyte function and glomerular filtration [51], as well
as contain nsSNPs which display linkage to kidney disease [52].
This study illustrates the importance of accounting for fine-scale
phenotypic structure. Although the current GWAS paradigm is
based on the testing of one phenotype and one marker at a time,
the quantitative phenotype profiles of individuals and correspond-
ing biological samples are rapidly expanding in scope and depth.
We are being faced with more complex multivariate phenotypic
information, and biologically heterogeneous phenotypes can now
be fine-mapped to reveal more informative patterns of association.
Powerful statistical approaches that leverage the network covari-
ance can provide novel insights and link genetics with disease.
Materials and Methods
Cohorts
The Cardiovascular Risk in Young Finns Study (YFS) is a
population based prospective cohort study. It was conducted at 5
university departments of medical schools in Finland (i.e. Turku,
Helsinki, Kuopio, Tampere and Oulu), with the aim of studying
the levels of cardiovascular risk factors in children and adolescents
in different parts of the country. The latest follow-up was
conducted in 2007. The serum samples for this metabolomics
study were collected at the latest follow up. The study and data
collection protocols have been described in detail in [10]. The YFS
study protocols have been approved by local ethics committees.
The Northern Finland Birth Cohort 1966 (NFBC66) has been
described in detail previously [11]. The original study design
focused to study factors affecting pre-term birth, low birth weight,
and subsequent morbidity and mortality. Mothers living in the two
northern-most provinces of Finland were invited to participate if
they had expected delivery dates during 1966. Individuals still
living in the Helsinki area or Northern Finland (N=4,703) were
asked to participate in a detailed biological and medical
examination as well as a questionnaire at the age of 31 years.
The NFBC66 study protocols have been approved by local ethics
committees.
The subjects used in the adipose tissue eQTL analysis were
obtained from the EUFAM study (European Multicenter Study of
Familial Dyslipidemias) database [30] including a Finnish cohort
with familial low HDL-C phenotype. The Ethical Committee of
the Department of Medicine, Helsinki University Central Hospital
approved the EUFAM study. Top and bottom 10
th percentiles of
HDL-C concentrations (Finnish population age and sex specific
percentiles) were used to define the high and low HDL-C groups,
respectively, and subject who were not matched for BMI were
removed. Subcutaneous adipose tissue biopsies were obtained
from 54 individuals. Out of these, 35 individuals had low HDL-C
and 19 individuals high HDL-C. Individuals in both low and high
HDL-C groups were matched by age and gender. Fat biopsies
were collected, RNA extracted and quantified as previously
described [53]. RNA labeling, array processing and scanning were
done according to the standard protocol by Affymetrix using HG-
U133 (Plus 2.0) arrays. Pre-processing of the expression data was
done using GC-RMA normalization. Genotyping was performed
using the HumanCNV370v1_C platform at the Broad Institute.
SNPs with genotype rate ,90% were excluded from the analyses
and samples were removed if fewer than 95% of SNPs could be
genotyped in them.
In the Tampere vascular study (TVS), vascular samples were
collected from patients undergoing peripheral vascular surgery due
to symptomatic atherosclerosis (cerebrovascular disease due to
carotid stenosis, peripheral arterial disease). All of these patients
had a polyvascular disease which had affected at least two different
vascular beds. Control samples were taken from left internal
thoracic arteries (LITA) during coronary artery by-pass surgery
(n=25). Atherosclerotic plaques were collected by endarterectomy
from the following arterial sites: femoral artery (n=24) carotid
artery (n=29) and abdominal aorta (n=15) all together from a
total of 93 patients. The vascular samples were classified according
to the American Heart Association classification (AHA) [54]. The
carotid and femoral artery samples were of type V or VI, aortic
samples were type VI and all control vessels were macroscopically
and microscopically healthy. The samples were taken from
patients subjected to open vascular surgical procedures at the
Division of Vascular Surgery, Tampere University Hospital. The
study was approved by the Ethics Committee of Tampere
University Hospital. All patients gave informed consent.
The HLC and BxH-ApoE data was obtained from the Sage
BioNetworks repository. A detailed description of the HLC data
can be found here [31,32]. Detailed information on mouse
experiments and sample handling can be obtained here [34,35].
An outlier with extreme lesion area (Z-score=4.166,
P=1.5610
25) was removed from analysis. Inclusion of the outlier
did not affect significance.
NMR metabolomics
The samples from the NFBC66, YFS and DILGOM cohorts
were analyzed using the same high-throughput serum NMR
metabolomics platform [17] providing information on lipoprotein
subclass distribution and lipoprotein particle concentrations, low-
molecular-weight metabolites such as amino acids, 3-hydroxybu-
tyrate, and creatinine, and detailed molecular information on
serum lipids including free and esterified cholesterol, sphingomy-
elin, saturation and v-3 fatty acids. Further details of the NMR
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identifications have been described previously [17,29].
Metabolomic data processing
Individuals known to be on lipid-lowering therapy or pregnant
were excluded from analysis. To calculate residuals for all
metabolites, each study included the following as covariates:
gender, age (only YFS, the NFBC66 is a birth cohort), and
loadings of the first 10 principal components from genetic data to
correct for cryptic population stratification. Residuals were
normalized using an inverse normal transformation to have a
mean of zero and a standard deviation of 1. In combining the
metabolomic data for the YFS and NFBC66, residuals for all
metabolites also included the cohort as a covariate. Processing of
metabolites from the DILGOM cohort has been described
previously [29].
Genotyping and imputation
The YFS and NFBC66 cohorts studied were genotyped using
standard protocols on the Illumina 670 BeadArray and Illumina
370CNVduo (Illumina, Inc. San Diego, CA, USA) respectively.
Prior to imputation, stringent quality filtering was employed for
each cohort. Quality control was performed independently for
each study prior to imputation. Low quality SNPs (.5%
missingness) and poor DNA samples (.5% individual missingness)
were removed. In addition, individuals with high genomic
heterozygosity (indicative of sample contamination), gender
discrepancies or closely related individuals were removed from
the data.
Genotype imputation was performed using the MACH
algorithm [14] and the CEPH reference panel from HapMapII
[15]. After filtering, sample numbers were 1,905 and 4,703 for the
YFS and NFBC66 cohorts respectively. After imputation, SNPs
were filtered within each cohort via the estimated squared
correlation between imputed and true genotypes (Rsq,0.30),
estimated minor allele frequency (MAF,0.01), and Hardy-
Weinberg equilibrium exact test (P,1.0610
26). After SNP
filtering, 2,406,682 and 2,360,512 SNPs in the YFS and NFBC66
cohorts respectively were taken forward for further genome-wide
analyses. The intensity cluster plots for the top, directly-genotyped
SNPs were visually inspected for failures in genotype assay and
calling.
Metabolite clustering
In order to define matrices of related endogenous variates,
groupings of metabolites must be defined. Normalized metabolite
measurements across the YFS and NFBC66 cohorts were pooled,
and the metabolite-metabolite Pearson correlation matrix was
hierarchically clustered. From the resulting dendrogram, metab-
olite cluster detection was done using a dynamic tree cutting
algorithm [18] with a minimum cluster membership of one
metabolite. We selected the dynamic tree cutting algorithm
because it has been shown to outperform other popular methods
in simulations as well as give biologically relevant results on real
data [29,55,56]. In order to maximize power to detect associa-
tions, Ferreira and Purcell showed that, within a phenotype set,
one should maximize both the number of phenotypes and the level
of correlation between phenotypes [4], however in practice these
two parameters are inversely related. That is, given a of phenotype
measures and individuals, increasing the number of phenotype
clusters leads to increasing correlation within clusters and vice
versa. For the dynamic tree cut algorithm, we investigated the
sensitivity of cluster splitting using the deepSplit parameter. Lower
integers values of deepSplit correspond to lower sensitivity for cluster
splitting and thus fewer clusters. Both high and low sensitivity
(deepSplit=4 and deepSplit=0, respectively) for cluster splitting were
explored using the YFS discovery cohort. The high setting
assigned 11 metabolic networks (Figure S1) whereas the low
setting assigned 5 metabolic networks (Figure S7). Both clusterings
were empirically assessed using the multivariate test above, and
both settings detected the same number of loci at genome-wide
significance. This was consistent with the inverse relationship
between intra-cluster correlation and number of metabolites per
cluster. Given no difference in locus detection, we considered the
biological interpretation of the clusters. We noted that the low
setting could not differentiate TG-rich VLDL particles nor lipid
poly-unsaturation and conflated various energy metabolites
with small HDL metabolism. Since it presented more straight-
forward biological interpretation, we proceeded to downstream
analysis with the high sensitivity, corresponding to 11 metabolic
networks.
Statistical analysis
Association testing of SNPs and metabolites was done using two
strategies: univariate linear regression and multivariate Canonical
Correlation Analysis (CCA). For the former, we used the standard
framework Yi~azbXizei where Yi is the normalized metabolite
measure for individual i, Xi is the genotype of the individual at a
given SNP (encoded as 0, 1, or 2 for the number of minor alleles),
and ei is a normally distributed random variable with mean equal
to zero and constant variance. To implement linear regression, we
used the PLINK analysis software [57]. The reported P values
assume a NULL hypothesis of no association, b=0.
When testing hypotheses that include multiple endogenous
variables, the relationships among the endogenous variables must
be taken into account in addition to those between the endogenous
and exogenous variables. Given these two sets of variables, the aim
is to simultaneously find the best predictor of the linear functions
of one set as well as the linear function of the other set it best
predicts. This yields a pair of variates which are referred to as the
first pair of canonical variates. Using the residuals of these linear
functions, the process can be repeated to obtain the second pair of
canonical variates, and so on. The full sequence of these pairs of
variates and their correlations then fully describe the invariant
relationships between the endogenous variable set and the
exogenous variable set [58].
For multivariate testing, we use the CCA framework imple-
mented in the PLINK.multivariate analysis tool [4] and the R
statistical programming language. In this case, the exogenous set
consists of only one variable, the SNP, and consequently only one
pair of canonical variates is calculated.
Wilks’ lambda (l) is a multivariate analogy of the F-test in one-
way analysis of variance. In a genetic setting, l is a statistic which
tests for differences between the means of the three genotype
groups (AA, AB, and BB) on a combination of endogenous variates
(a network of metabolite variables). In this case, l=12r
2 where r
is the canonical correlation coefficient between the SNP and the
network of metabolite variables. The calculation of a P-value arises
from a transformation of Wilks’ lambda into a statistic which is
approximately F distributed.
Genomic inflation of test statistics can be an indicator of subtle
biases in the data and testing (e.g. cryptic population structure). To
assess genomic inflation, we compared our observed distribution of
2log10(P) values to that expected in the absence of association. A
linear model was then fitted to the lowest 90% of the distribution
and genomic inflation was taken as the slope of the fitted line.
Table S1 gives genomic inflation values for multivariate testing of
YFS, NFBC66 and meta-analysis across all metabolic networks.
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top significantly associated SNP. To determine the independence
of the locus-network signals, conditional multivariate association
analysis was used for signals either at 4q13.3, close to LIPC (i.e.
AQP9 variants), or close to FADS1/2/3 (i.e. CD5/CD6 and
INCENP/FTH1/BEST1 variants). For the top SNP(s) at a
proximal locus (Table S2), each metabolite in a network was
regressed onto the proximal SNP(s) and the resulting residuals
were used as endogenous variables in the multivariate test of the
target locus. An attenuated signal indicates non-independence, e.g.
the SNPs tag the same causal variant. As a result, two loci (CD5/
CD6 and INCENP/FTH1/BEST1) were largely attenuated and not
regarded as independent from the FADS1/2/3 locus.
Due to the different number of statistical tests, genome-wide
significance differs between multivariate and univariate testing.
Here, as the basis of genome-wide significance, we use the
common threshold of 5.0610
28, derived from the number of
independent common haploblocks in genomes of European
descent [59]. Univariate testing of all 130 metabolites, implies a
Bonferroni corrected significance level of 5.0610
28/
130=3.8610
210. Multivariate testing of the metabolic networks
we identify here (N=11) gives a Bonferroni corrected significance
level of 5.0610
28/11=4.5610
29.
Analysis of the DILGOM cohort considered the bead-weighted
and quantile normalized gene expression data from the Illumina
HT-12 expression array as described previously [55] and
metabolomic measures also described previously [29]. Only those
metabolites which were part of the original metabolic network
associated with a particular locus were considered. For example,
because genetic variation at SERPINA1 was associated with
metabolic networks 1 and 2, expression of SERPINA1 was only
tested for association with metabolites from networks 1 and 2.
Since loci were associated with different metabolic networks,
different numbers of tests were performed for each candidate gene.
We therefore implemented appropriate multiple testing thresholds
for each gene where significance was set at P,(0.05/total_num-
ber_metabolites_in_tested_networks).
For the EUFAM study, statistical eQTL analyses were
performed using a linear regression model adjusting for the
gender, BMI, and low/high HDL-C affection status. Probe
intensities were treated as dependent and genotypes as indepen-
dent variables. The comparison of gene-expression between the
low and high HDL-C groups was performed using a linear
regression model. Fold change for each probe was calculated by
dividing the mean probe intensity in the low HDL-C group by the
mean probe intensity in the high HDL-C group.
For the TVS study, all vascular specimens were immediately
frozen and RNA was extracted as previously described [60]. RNA
was reverse transcribed into cRNA, biotin-UTP labelled using the
Illumina TotalPrep RNA Amplification Kit (Ambion) and cRNA
hybridized to the Illumina HumanHT-12 v3 Expression Bead-
Chip. BeadChips were scanned with the Illumina iScan system.
Data processing was conducted using R language and appropriate
Bioconductor modules. Robust multi-array averaging (RMA) [61]
was used to correct negative intensity values after background
subtraction. Between arrays normalization was done using robust
spline normalization (RSN) [61]. Quality control was performed
using sample clustering and multi-dimensional scaling. Seven
outliers were removed due to low expression profiles, 4 from
carotid artery group and 3 from LITA group.
Fold changes (FCs) for differentially expressed genes were
calculated from log2-transformed median expression values
between case (carotid, abdominal, femoral) and control group
(LITA), and the significance of the differences were evaluated with
non-parametric Mann-Whitney U test due to non-normal
distribution of expression values and relatively small sample sizes
of TVS. If there were more than one probe presenting a gene in
the expression chip, the probe with highest median expression
value was selected for FC calculation.
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